Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Medicenna Therapeutics Corp. (MDNAF) had Return on Tangible Equity of -47.91% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-3.54M |
|
-- |
|
-- |
|
$3.97M |
|
$-3.97M |
|
$0.43M |
|
$-3.54M |
|
$-3.54M |
|
$-3.54M |
|
$-3.54M |
|
$-3.54M |
|
$-3.54M |
|
$-3.97M |
|
$-3.95M |
|
83.41M |
|
83.41M |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$12.97M |
|
$0.00M |
|
$0.12M |
|
$13.10M |
|
$3.24M |
|
-- |
|
$2.42M |
|
$5.66M |
|
$7.43M |
|
$7.40M |
|
$7.43M |
|
83.41M |
|
| Cash Flow Statement Financials | |
$-6.16M |
|
-- |
|
$0.01M |
|
$18.03M |
|
$11.43M |
|
$-6.60M |
|
$0.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.16M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-47.68% |
|
|
Return on Tangible Equity |
-47.91% |
-27.07% |
|
-47.68% |
|
$0.09 |
|
$-0.07 |
|
$-0.07 |
|